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Sirolimus is a potent immunosuppressive agent used for the prophylaxis of transplant rejection. The cellular action of sirolimus is mediated by binding to the FK506-binding protein (i.e., FKBP12) and blocking signals induced by mammalian target of Rapamycin and arresting cell cycle progression from G1 to S phase transition (29) . Recent studies have demonstrated that sirolimus has a beneficial effect in preventing restenosis following angioplasty in animal models and in clinical trials where sirolimus-coated stents have been shown to inhibit intimal thickening in patients with coronary artery disease (9, 12, 20, 41) . Furthermore, some studies showed that sirolimus reduces atherosclerotic lesion size in apoE-null mice, whether administered intraperitoneally (3, 7) or orally (28) . Although Elloso et al. (7) have reported increased low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol in sirolimus-treated apoE-null mice, interestingly, Castro et al. (3) found no significant effect of sirolimus on circulating lipids, including LDL cholesterol, HDL cholesterol, very LDL cholesterol, and intermediate density lipoprotein cholesterol. On the other hand, sirolimus did not aggravate hypercholesterolemia in fat-fed apoE-null mice (3, 7, 25, 26) while increasing circulating triglyceride levels in the same animal model (25) . These discrepancies suggest that the anti-atherosclerotic effect of sirolimus could be related to the change of local cholesterol metabolism in the tissues mediated through its anti-proliferative and anti-inflammatory effects. This study particularly addresses the question how the anti-inflammatory effects of sirolimus modify the lipid-mediated vascular injury through its effects on intracellular cholesterol homeostasis.
In most cells, intracellular lipid content is governed by tight regulation of cholesterol influx and efflux pathways. The intracellular level of cholesterol is controlled by the uptake and synthesis of cholesterol through feedback regulation. Recent studies strongly indicated that atherogenesis is initiated by the interplay between cholesterol and cellular secretion of cytokines (especially IL-6) and apolipoprotein-E within the arterial wall (14) . Ruan et al. (34, 37, 38) also reported that inflammatory cytokines could cause lipid accumulation by increasing native LDL uptake via LDL receptor (LDLr) or reducing efflux of intracellular lipid via ATP-binding cassette transporter A1 (ABCA1) in human mesangial cells. Therefore, the present investigation was undertaken to evaluate whether sirolimus ameliorates the imbalance of intracellular cholesterol homeostasis in human VSMCs mediated by inflammatory mediators.
MATERIALS AND METHODS
Cell culture. The primary human VSMCs from coronary artery (TCS cell works, Buckinghamshire, UK) were cultured in a basal medium in T75 flasks (Falcon, UK) supplemented with 5% fetal bovine serum, insulin, human epidermal growth factor, human fibroblast growth factor, 2 mmol/l L-glutamine, 0.5 ml 25 mg/ml gentamicin, and 50 g/ml amphotericin B. Cell cultures were maintained in a humidified 95% air-5% CO 2 incubator at 37°C, and the medium was changed every 48 h. Cells were subcultured with 0.25% trypsin-0.01% EDTA when cells were grown to subconfluence. The cells and all reagents for cell culture were obtained from TCS Cell Works. Recombinant interleukin-1 (IL-1␤, 1.0 -3.3 ϫ 10 8 U/mg) was obtained from R&D Systems (Europe, Abingdon, UK). Sirolimus (914.19 mol wt, code AY-22989-39) was supplied by Wyeth Pharmaceutics. All experiments were carried out in serum-free DMEM/F12 (1:1) medium containing 0.2% fatty acid-free BSA (Sigma, Poole, Dorset, UK).
Lipoprotein preparation. Plasma was collected from healthy human volunteers, and LDL was isolated by sequential ultracentrifugation as described in our previous publication (36) . The study protocol was approved by the Institutional Review Board of Royal Free and Medical School, University College London and adhered to the tenets of the Declaration of Helsinki for experiments involving human samples. Antioxidants (100 mol/l of EDTA and 20 mol/l BHT) were added into the fresh LDL to prevent oxidation. The extent of lipid peroxidation of the LDL was estimated as the concentration of thiobarbituric acid reactive substances as described previously, and the results were expressed as nmoles of malondialdehyde per milligram LDL (nmol MDA/mg LDL). The levels of thiobarbituric acid reactive substances in native LDL used in the study were Ͻ0.1 nmol MDA/mg LDL.
Morphological examination. VSMCs were plated in chamber slides for tissue culture (Becton Dickinson Labware) and incubated in serum-free experimental medium with native LDL in the absence or presence of cytokines and cytokine plus sirolimus. After 24 h incubation, the cells were washed three times in phosphate-buffered saline (PBS), fixed for 30 min with 5% formalin solution in PBS, stained with Oil Red O for 30 min, and counterstained with hematoxylin for another 5 min. Finally, the cells were examined by light microscopy.
Quantitative measurement of intracellular free cholesterol-cholesterol ester. VSMCs were plated in six-well plates (Nunc, Naperville, IL). The cells then were incubated in serum-free DMEM/F12 (1:1) medium with 200 g/ml of native LDL or 5 g/ml of IL-1␤ plus native LDL (200 g/ml) in the absence or presence of 10 or 100 ng/ml sirolimus for 24 h. The total and free cholesterol were analyzed using the method described by Gamble et al. (10) . In brief, the cells were collected and washed twice with PBS; lipids were extracted by addition of 1 ml chloroform-methanol (2:1) to the cell pellet. After sonification, the samples were centrifuged, and the lipid phase was collected. The samples were dried in vacuum and then dissolved in 2-propanol containing 10% Triton X-100. Cholesterol ester was converted to free cholesterol by cholesterol ester hydrolase for determination of total cholesterol. Cholesterol oxidase was employed to generate H 2O2 from free cholesterol, and peroxidase was used to catalyze the reaction of H2O2 with 4-amino-antipyrine and phenol to yield a stable rose-color product. The concentration of total and free cholesterol per well was analyzed using a standard curve and normalized by total cell protein. The concentration of cholesterol ester was calculated using total cholesterol minus free cholesterol.
Cholesterol loading and efflux. VSMCs were loaded with 30 g/ml cholesterol, 1 g/ml 25-hydroxycholesterol, and 1 Ci/well [1␣, 2␣(n)- 3 H]cholesterol (Amersham, Little Chalfont, Bucks, UK) in serum-free medium for 48 h to equilibrate cellular cholesterol pools. After 48 h, fresh serum-free medium containing sirolimus (10 ng/ml or 100 ng/ml) was added in the presence or absence of the inflammatory cytokine IL-1␤ (5 ng/ml) for another 24 h. After this incubation period, cells were washed three times in PBS, and ApoA 1-mediated cholesterol efflux studies were immediately performed by adding fresh serum-free medium with or without 15 g/ml ApoA 1 (Calbiochem, Nottingham, UK) for 6 h. At the end of this incubation, the supernatant was collected and centrifuged at 13,000 rpm for 10 min to remove debris. Cells were lysed with 0.5 ml of 0.1 N NaOH. The radioactivity in both the supernatant and cellular lipid was measured by scintillation counting. ApoA 1-induced [ 3 H]cholesterol efflux was calculated by subtracting the radioactivity in supernatants without ApoA1 from the counts in supernatants containing ApoA1. The data were normalized by total [ 3 H]cholesterol radioactivity (including in supernatant and cell) and were expressed as a percentage of control.
Quantification of specific transcripts by real-time RT-PCR. Total RNA was isolated from cultured VSMCs using the guanidiniumphenol-chloroform method. Total RNA (500 ng) was used as a template for RT-PCR. The RT reaction was set up using a kit from Applied Biosystems (Warrington, Cheshire, UK). After cDNA synthesis by RT, cDNA was split for the separate amplification for target genes using specific primers designed by Taqman Primer Express Software V2.0 as shown in Table 1 . Real-time PCR was performed in an ABI 7000 using SYBR Green PCR kit according to the manufacturer's protocol (Applied Biosystems). After the PCR, a dissociation curve (melting curve) was constructed in the range of 60°C to 95°C. Relative amount of mRNA was calculated using the comparative threshold cycle (C t) method (⌬⌬Ct method). The amplification efficiencies of the target and reference were shown to be approximately equal with a slope of log input amount to C t Ͻ 0.1. Controls consisting of H2O or samples that were not reversely transcribed were negative for target and reference. 
Western blot analysis. Identical amounts of total protein from cultured VSMCs extracts were denatured and then subjected to electrophoresis on a 5% stacking and 8% separating SDS polyacrylamide gel. Electrophoretic transfer to nitrocellulose was accomplished at 100 V, 350 mA for 1 h in 25 mmol/l Tris, pH 8.3, 192 mmol/l glycine, 0.1% SDS, and 20% methanol. The membrane was then blocked with 2% blocker (Amersham Bioscience) for 1 h at room temperature and subjected to Western blotting analysis using chicken anti-human LDLr polyclonal antibody (Abcam, Cambridge, UK), rabbit anti-human VLDL receptor (VLDLr) polyclonal antibody(Santa Cruz Biotechnology) with horseradish peroxidaselabeled secondary antibodies (Abcam). Actin was also examined using a rabbit anti-actin antibody (Sigma, Poole, Dorset, UK) with a second antibody of goat anti-rabbit horseradish peroxidase-linked IgG (New England Biolabs, Herts, UK). Finally, the signals were detected using ECL advanced system (Amersham Bioscience).
Determination of IL-6, TNF-␣, IL-8, and MCP-1 release. VSMCs in six-well plates were grown to confluence and then cultivated in serum-free medium containing 0.2% BSA (fatty acid free) for 24 h before the experiment. After addition of the stimuli, cells were incubated for 24 h, and then the supernatants of conditioned medium were collected and frozen at Ϫ70°C. Assays for IL-6, tumor necrosis factor (TNF)-␣, IL-8, and monocyte chemoattractant protein-1 (MCP-1) were performed with an Enzyme-Linked Immunosorbent Assay Kit (R&D Systems) according to the manufacturer's instructions. The results were normalized with the concentration of total cell protein per well.
Data analysis. In all experiments, groups of data were evaluated for significance by one-way analysis of variance (ANOVA). Data were considered significant if the P value Ͻ 0.05.
RESULTS
Using Oil Red O staining, we checked the morphological change of VSMC loaded with native LDL in the presence or absence of inflammatory cytokine. We found that IL-1␤ significantly increased lipid droplets accumulation of VSMC (Fig. 1B) . However, sirolimus reduced lipid droplet accumulation of VSMC caused by IL-1␤ (Fig. 1D) . Furthermore, quantitative intracellular cholesterol analysis confirmed that sirolimus reduced cholesterol ester accumulation induced by IL-1␤ in VSMCs, and sirolimus provided a protective role in decreasing lipid accumulation mediated by inflammatory cytokine in VSMCs (Fig. 1E) . VSMCs were cultured for 24 h in serum-free medium containing 200 g/ml of native LDL in the absence (control; Ctr) or presence of 5 ng/ml of IL-1␤ or 10 ng/ml of sirolimus or 5 ng/ml of IL-1␤ plus 10 ng/ml sirolimus. Intracellular free cholesterol and cholesterol ester were assayed as described in MATERIALS AND METHODS. Values are means Ϯ SD of duplicate wells from 4 experiments. *P Ͻ 0.05 vs. control. **P Ͻ 0.01 vs. control. ***P Ͻ 0.01 vs. IL-1␤.
To investigate the potential mechanisms of these phenomena, we investigated effects of sirolimus on the gene expression of lipoprotein receptors that mediate cholesterol uptake. Sirolimus significantly reduced VLDLr and LDLr gene expression in VSMCs, even in the presence of IL-1␤ ( Fig. 2A) . We also checked gene expression of type A scavenger receptor CD 36 ; however, we found no significant changes (results not shown). The influence of sirolimus on the protein expression of VLDLr and LDLr was examined by Western blotting. Sirolimus reduced VLDLr and LDLr protein expression, especially in the presence of IL-1␤, which is consistent with the mRNA results (Fig. 2, B and C) .
We also examined the effects of sirolimus on intracellular cholesterol efflux under inflammatory stress. We found that IL-1␤ (5 ng/ml) reduces ApoA 1 -mediated cholesterol efflux from lipid-loaded VSMCs. However, sirolimus (10 ng/ml, 100 ng/ml) can restore the suppression induced by inflammation (Fig. 3) . Since ABCA1 and ABCG1 are the major players in mediating intracellular cholesterol efflux, we evaluated the effect of sirolimus on ABCA1 and ABCG1 mRNA expression. We found that sirolimus increased both ABCA1 and ABCG1 gene expression in lipid-loaded VSMCs even in the presence of IL-1␤, which significantly reduced ABCA1 mRNA steadystate level (Fig. 4, A and B) . These results suggest that sirolimus restores the suppression of ABCA1 and ABCG1 pathways induced by IL-1␤.
Interestingly, sirolimus also inhibited both mRNA (Fig. 5 , A and B) and protein (Fig. 6, A-C) expression of inflammatory cytokines in non-lipid-loaded and lipid-loaded VSMCs, suggesting that sirolimus also decreases lipid accumulation by inhibiting inflammatory mediators. All of our results suggest that sirolimus may play an important role in the maintenance of intracellular cholesterol homeostasis of VSMCs by several different mechanisms.
DISCUSSION
Activation of immune cells, excessive VSMC proliferation, and migration within the arterial wall are thought to play important role in neointimal thickening in both experimental animals models and humans (11) . Studies have demonstrated that sirolimus attenuated neointimal thickening in some animal The cholesterol-loaded cells were incubated in serum-free medium (control) or serum-free medium with 10 or 100 ng/ml of sirolimus or 5 ng/ml of IL-1␤ , or IL-1␤ (5 ng/ml) plus sirolimus (10 ng/ml) or IL-1␤ (5 ng/ml) plus sirolimus (100 ng/ml) for 24 h. The cholesterol efflux was measured. Data represent the means Ϯ SD of 4 independent experiments. *P Ͻ 0.01 vs. control, **P Ͻ 0.01 vs. IL-1␤ group. models of alloimmune and mechanical injury (3, 5) . Moreover, sirolimus reduced human coronary in-stent restenosis (15, 39) . Sirolimus also can directly inhibit the VSMC proliferation and migration that contribute to atherosclerosis (29) . Remarkably, sirolimus significantly reduced aortic cholesterol content (1) and atherosclerotic lesion size (3, 7, 28) in fat-fed apoE-null mice. Despite the demonstrated atheroprotective effect of sirolimus in ApoE-null mice, caution must be exercised regarding its possible clinical use in patients experiencing atherosclerosis, since several studies have shown that sirolimus can exacerbate preexisting hypercholesterolemia and hypertriglyceridemia in humans (13, 19, 21) . In this study, we examined the effect of sirolimus on intracellular cholesterol homeostasis in the presence of inflammatory cytokine IL-1␤ and determined whether this compound reduces intracellular lipid accumulation and foam cell formation in the human coronary artery smooth muscle cell, one of the main cells in atherosclerotic lesions.
IL-1␤ is a prototypic proinflammatory cytokine that plays an important role in vascular inflammation and the pathogenesis of atherosclerosis. IL-1␤ can be synthesized by macrophages, endothelial cells, and VSMCs, and the levels IL-1␤ in the vessel wall are also elevated in atherosclerosis (8, 17, 24) . It is well-known that IL-1␤ induces the production of cytokines and chemokines and increases the expression of adhesion molecules on endothelial cells, thus leading to the recruitment of inflammatory cells. In addition, IL-1␤ contributes to the development of tissue damage by stimulating cell proliferation and the release of matrix metalloproteases (18) leading to destabilization/and finally rupture of vulnerable atherosclerotic plaques. At a clinical level, circulating cytokines have a prognostic role since they are useful markers for predicting future coronary events in patients with advanced atherosclerosis and in patients after acute coronary syndromes (42) . More recently, it has been demonstrated that overexpression VSMCs were loaded with 30 g/ml cholesterol and 1 g/ml 25-hydroxy-cholesterol in serum-free medium for 48 h. After that, VSMCs were incubated in serum-free medium (control) or serum-free medium with 10 -100 ng/ml of sirolimus (Sir10, Sir 100) or 5 ng/ml of IL-1␤ (IL-1␤), or 5 ng/ml of IL-1␤ plus 10 -100 ng/ml of sirolimus (IL-1␤ ϩ Sir10, IL-1␤ ϩ Sir100) for 24 h. The mRNA expression of ABCA1 and ABCG1 was determined following the ⌬⌬Ct protocol for real-time RT-PCR as described in MATERIALS AND METHODS. ␤-Actin served as the housekeeper gene. Results represent the means Ϯ SD from 4 experiments. *P Ͻ 0.001 vs. control, **P Ͻ 0.001 vs. IL-1␤ group.
of sIL-1Ra, a natural inhibitor of IL-1, can inhibit the development of atherosclerotic lesions in ApoEϪ/Ϫ mice. By crossing ApoEϪ/Ϫ mice with IL-1RaϪ/Ϫ mice, this doubly deficient model exhibited a severe form of aortic inflammation with massive infiltration of macrophages in the adventitia, lipid accumulation in macrophages, and marked destruction of the elastic lamina. However, ApoEϪ/Ϫ IL-1Raϩ/ϩ developed atherosclerosis, whereas ApoEϩ/ϩ IL-1Ra Ϫ/Ϫ had no signs of atherosclerosis or vascular inflammation (18) .
We demonstrated that sirolimus reduced lipid droplets accumulation and cholesterol ester content in VSMCs caused by IL-1␤. We have demonstrated previously that IL-1␤ induces cholesterol esterification by increasing acyl-CoA:cholesterol acyl-transferase (ACAT) activity in VSMCs (35) . Taken together, these findings suggest that sirolimus may inhibit IL-1␤-induced cholesterol esterification.
We have also demonstrated that IL-1␤ increased VLDL receptor and LDL receptor mRNA and protein expression in VSMCs, suggesting that inflammatory cytokine IL-1␤ disrupted cholesterol homeostasis by increasing receptor-mediated cholesterol uptake. However, sirolimus decreased intracellular lipid accumulation of VSMCs by reducing mRNA and protein expression of VLDLr and LDLr even in the presence of IL-1␤. Our results also suggest that sirolimus increases intracellular cholesterol efflux by upregulating ABCA1 and ABCG1 gene expression in the presence of IL-1␤. Importantly, sirolimus overrode the suppression of cholesterol efflux induced by IL-1␤. Thus sirolimus may ameliorate imbalance of intracellular cholesterol homeostasis in VSMCs mediated by inflammatory cytokines, in agreement with the anti-atherosclerotic effect of sirolimus in some animal models and clinical studies of human cardiovascular diseases.
Our results may also partly explain some dose-dependent adverse effects of sirolimus, especially hyperlipidemia with a high plasma VLDL and LDL concentration in transplant patients after sirolimus treatment (13, 21, 22) . Sirolimus reduces lipids influx to peripheral cells such as VSMCs by inhibiting receptor-mediated uptake of LDL and VLDL, the carriers of cholesterol and triglyceride, respectively. We have also observed a reduction in VLDL and LDLr in hepatocyte cultures (not published). In addition, some studies have also reported that sirolimus alters the insulin signaling pathway by increasing adipose tissue lipase activity and/or decreasing lipoprotein lipase activity, resulting in increased hepatic synthesis of triglyceride, increased secretion of VLDL, and increased hypertriglyceridemia (23) . However, sirolimus also significantly increased cholesterol efflux from the cells through the ABCA1 and ABCG1 pathways as demonstrated here, which may reduce intracellular cholesterol level and increase HDL formation, which protects against atherosclerosis. Our in vitro studies demonstrate that sirolimus reduces intracellular cholesterol concentration of VSMCs despite its hyperlipidemic potential.
Inflammation is a risk factor for atherosclerosis (32) . We assumed that sirolimus inhibits inflammatory processes directly. Therefore, we examined the effect of sirolimus on the inflammatory cytokine excretion of VSMC by using IL-1␤ as stimulator. Our results showed that sirolimus directly inhibited mRNA expression of inflammatory cytokines IL-6, TNF-␣, IL-8, and MCP-1. The reduction of IL-6, IL-8, and MCP-1 protein levels was confirmed by ELISA assay (note: TNF-␣ level was too low to be measured in the supernatants of VSMC cultures). Some previous studies have also demonstrated effects of sirolimus on the expression and excretion of inflammatory cytokines and chemokines in mesangial Fig. 6 . Effect of sirolimus on the protein productions of inflammatory cytokines in VSMCs without or with lipid loading. VSMCs were preloaded with cholesterol as described in MATERIALS AND METHODS. Both normal and cholesterol-loaded VSMCs were incubated in serum-free medium (control) or serum-free medium with different concentrations (10 -100 ng/ml) of sirolimus (Sir10 and Sir100) or 5 ng/ml of IL-1␤ (IL-1␤) or 5 ng/ml of IL-1␤ plus different concentrations of sirolimus (IL-1␤ ϩ Sir10, IL-1␤ ϩ Sir100) for 24 h. Supernatants were collected and assayed for IL-6 (A), IL-8 (B), and MCP-1 (C) as described in MATERIALS AND METHODS. Results are expressed as means Ϯ SD of 4 independent experiments. *P Ͻ 0.05 vs. control, **P Ͻ 0.001 vs. control, ***P Ͻ 0.05 vs. IL-1␤ group, ****P Ͻ 0.001 vs. IL-1␤ group. cells and in a macrophage cell line (43) , as well as in transplant models (27, 44) .
It is clear that VSMCs in mature, normal blood vessels exhibit a differentiated, quiescent, contractile morphology, but injury induces a phenotypic modulation toward a proliferative, dedifferentiated, migratory phenotype with upregulated extracellular matrix protein synthesis (synthetic phenotype), which contributes to intimal hyperplasia. Martin et al. (17a) have demonstrated that sirolimus treatment induces differentiation in cultured synthetic phenotype VSMCs from multiple species. VSMCs treated with sirolimus assumed a contractile morphology, quantitatively reflected by a 67% decrease in cell area. Total protein and collagen synthesis were also inhibited by sirolimus. Sirolimus induced expression of the VSMCs differentiation marker contractile proteins smooth muscle (SM) ␣-actin, calponin, and SM-myosin heavy chain (SM-MHC), as observed by immunoblotting and immunohistochemistry. The interaction among mammalian target of Rapamycin pathway, cell phenotype, and cholesterol hemostasis need to be investigated.
In summary, our results suggest that inflammatory cytokines can cause lipid accumulation by disrupting cholesterol homeostasis in VSMCs. Sirolimus prevents this lipid accumulation by 1) inhibiting gene and protein expression of VLDLr and LDLr; 2) upregulating ABCA 1 and ABCG1 gene expression thereby overriding the reduction in cholesterol efflux induced by IL-1␤; and 3) reducing inflammatory cytokine production, which may provide an additional mechanism for the antiatherosclerotic effect of this compound.
